Here, we found that our proposed composite biomarker (hsa-miR484, hsa-miR-25-3p, hsa-miR-451a, ApoE, and YKL-40) could distinguish between patients prone to anaphylaxis and healthy individuals with a higher accuracy than any other available model. This evidence concerns the gene APOE and anaphylaxis.